Kindred Biosciences Inc (KIN) Gross Profit Margin starting from the second quarter 2021 to second quarter 2020, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Kindred Biosciences Inc   (NASDAQ: KIN)


Kindred Biosciences Inc 's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

KIN Gross Profit Margin (Jun 30 2021)
Q2 		(Mar 31 2021)
Q1 		(Dec 31 2020)
Q4 		(Sep 30 2020)
Q3 		(Jun 30 2020)
Q2
Y / Y Revenue Change -91.06 %
Seq. Revenue Change 47.68 %
Revenue In Millions $3.54
Gross Profit Margin 81.93 %
Gross Profit Margin Total Ranking # 507
Gross Profit In Millions $2.90
Y / Y Gross Profit Change -92.61 %
Seq. Gross Profit Change 60.55 %


Commenting Second Quarter 2021 Gross Profit Margin
Kindred Biosciences Inc Gross Profit grew by 60.55 % in Q2 sequentially to 3 millions, while Revenue increased by 47.68 %, this led to improvement in the company's Gross Profit Margin to 81.93 %, above the Kindred Biosciences Inc average Gross Profit Margin.


Observing second quarter 2021 results within Major Pharmaceutical Preparations industry 62 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 507, from total ranking in the previous quarter at 769.
Learn about Gross Margin
KIN's Gross Profit Margin second quarter 2021 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 63
Healthcare Sector # 105
Overall # 493

Gross Profit Margin Statistics
High Average Low
99.08 % 81.48 % 59.94 %
(Jun 30 2020)   (Dec 31 2020)


KIN Gross Income Trends • More of KIN's Profitabilty Ratios • KIN Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
KIN's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
KIN's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for KIN's Competitors
Gross Profit Margin Profit Margin for Kindred Biosciences Inc 's Suppliers
Gross Profit Margin Profit Margin for KIN's Customers

You may also want to know
KIN's Annual Growth Rates KIN's Profitability Ratios KIN's Asset Turnover Ratio KIN's Dividend Growth
KIN's Roe KIN's Valuation Ratios KIN's Financial Strength Ratios KIN's Gross Profit Growth
KIN's Roa KIN's Inventory Turnover Ratio KIN's Growth Rates KIN's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Jun 30 2021, within Major Pharmaceutical Preparations Industry Gross Profit MarginJun 30 2021 MRQ Gross ProfitJun 30 2021 MRQ Revenue
Biora Therapeutics Inc   100.00 %$ 0.463  Millions$ 0.463  Millions
Macrogenics Inc   99.93 %$ 30.735  Millions$ 30.757  Millions
Bridgebio Pharma Inc   99.80 %$ 53.915  Millions$ 54.024  Millions
Ptc Therapeutics inc   99.74 %$ 116.376  Millions$ 116.676  Millions
One World Products Inc   99.59 %$ 0.042  Millions$ 0.042  Millions
Karyopharm Therapeutics Inc   99.56 %$ 22.501  Millions$ 22.601  Millions
Rigel Pharmaceuticals Inc  99.51 %$ 26.137  Millions$ 26.266  Millions
Intercept Pharmaceuticals inc   99.36 %$ 95.958  Millions$ 96.576  Millions
Omeros Corporation  98.81 %$ 28.481  Millions$ 28.823  Millions
Corcept Therapeutics Inc  98.49 %$ 90.204  Millions$ 91.588  Millions
Global Blood Therapeutics Inc.  98.43 %$ 46.807  Millions$ 47.555  Millions
Y mabs Therapeutics inc   98.17 %$ 10.751  Millions$ 10.951  Millions
Abvc Biopharma Inc   97.95 %$ 0.031  Millions$ 0.031  Millions
Acadia Pharmaceuticals Inc   97.81 %$ 112.695  Millions$ 115.221  Millions
Ionis Pharmaceuticals Inc   97.65 %$ 122.792  Millions$ 125.750  Millions
Adamas Pharmaceuticals Inc  97.60 %$ 21.445  Millions$ 21.972  Millions
Avalo Therapeutics Inc   97.53 %$ 3.272  Millions$ 3.355  Millions
Myovant Sciences Ltd   97.49 %$ 40.031  Millions$ 41.063  Millions
Travere Therapeutics Inc   96.98 %$ 52.966  Millions$ 54.617  Millions
Ultragenyx Pharmaceutical Inc   96.39 %$ 83.839  Millions$ 86.975  Millions
Eton Pharmaceuticals Inc   95.57 %$ 2.931  Millions$ 3.067  Millions
Strongbridge Biopharma plc  95.35 %$ 9.575  Millions$ 10.042  Millions
Aurinia Pharmaceuticals Inc   95.35 %$ 6.312  Millions$ 6.620  Millions
Uniqure N v   95.00 %$ 440.690  Millions$ 463.868  Millions
Deciphera Pharmaceuticals Inc   94.59 %$ 22.298  Millions$ 23.573  Millions
Kadmon holdings inc   94.42 %$ 0.186  Millions$ 0.197  Millions
Sellas Life Sciences Group Inc   94.25 %$ 1.638  Millions$ 1.738  Millions
Rvl Pharmaceuticals Plc  93.84 %$ 10.801  Millions$ 11.510  Millions
Zogenix Inc   93.50 %$ 17.567  Millions$ 18.789  Millions
Emmaus Life Sciences Inc   93.37 %$ 6.059  Millions$ 6.489  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.